Individual Study / OPTIMAAL

Optimal Trial in Myocardial Infarction with Angiotension II Antogonist, Losartan

Optimal Trial in Myocardial Infarction with Angiotension II Antogonist, Losartan

Initiatives -
A multicentre, randomised trial to test the hypothesis that the angiotensin II antagonist losartan would be superior or non-inferior to the ACE inhibitor captopril in decreasing all-cause mortality in high-risk patients after acute myocardial infarction. *Note: All published information has been collected from the article referenced in the Marker Paper box below. Therefore, there may be variations with more advanced versions of the study. *

Members

Download
Investigators Contacts
  • Dr. Prof. Kenneth Dickstein
    University of Bergen

Design

Study design
Clinical trial cohort
Follow Up
A mean follow-up of 2.7 years:

Marker Paper

Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002 Sep 7;360(9335):752-60. doi: 10.1016/s0140-6736(02)09895-1.

PUBMED 12241832

Recruitment

Sources of Recruitment
  • Individuals

Number of participants

Number of participants
5,477
Number of participants with biosamples
Supplementary Information
Patients were 50 years of age or older (mean age 67.4 years [SD 9.8]), with confirmed acute myocardial infarction and heart failure during the acute phase or a new Q-wave anterior infarction or reinfarction, were recruited from 329 centres in seven European countries.

Access

Availability of data and biosamples

Data
Biosamples
Other